Prestige Consumer Healthcare (NYSE:PBH) VP Sells $66,372.93 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jeffrey Zerillo also recently made the following trade(s):

• On Tuesday, May 5th, Jeffrey Zerillo sold 346 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $55.32, for a total value of $19,140.72.
• On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $65.93, for a total value of $65,930.00.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $52.53 on Friday. The firm has a market capitalization of $2.49 billion, a P/E ratio of 13.90, a P/E/G ratio of 1.58 and a beta of 0.40. Prestige Consumer Healthcare Inc. has a 1-year low of $51.24 and a 1-year high of $89.37. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The business’s 50-day simple moving average is $60.23 and its 200-day simple moving average is $61.92.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The firm had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.22 earnings per share. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.54 EPS for the current year.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its stake in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the period. Bayforest Capital Ltd purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $29,000. First Horizon Corp purchased a new position in shares of Prestige Consumer Healthcare in the third quarter valued at $32,000. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after acquiring an additional 283 shares in the last quarter. Finally, Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth about $35,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PBH has been the topic of a number of research reports. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Finally, Oppenheimer lowered their target price on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a research note on Thursday. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $74.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).